Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

OBJECTIVE—To evaluate the dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin in drug-naïve patients with inadequately controlled type 2 diabetes. RESEARCH DESIGN AND METHODS—This double-blind, placebo-controlled, multicenter study included 329 patients with poorly controlled diabetes randomized to...

Descripción completa

Detalles Bibliográficos
Autores principales: DeFronzo, Ralph A., Fleck, Penny R., Wilson, Craig A., Mekki, Qais
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2008
Materias:
Emerging Treatments and Technologies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584188/
https://www.ncbi.nlm.nih.gov/pubmed/18809631
http://dx.doi.org/10.2337/dc08-1035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584188/
https://www.ncbi.nlm.nih.gov/pubmed/18809631
http://dx.doi.org/10.2337/dc08-1035

Ejemplares similares